ProfileGDS5678 / 1434060_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 77% 76% 76% 76% 75% 78% 66% 78% 78% 79% 76% 80% 76% 80% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.2216677
GSM967853U87-EV human glioblastoma xenograft - Control 25.1082876
GSM967854U87-EV human glioblastoma xenograft - Control 35.0926576
GSM967855U87-EV human glioblastoma xenograft - Control 45.2510576
GSM967856U87-EV human glioblastoma xenograft - Control 54.9854875
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.1760278
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.047666
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.3020478
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.4185978
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.6249879
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.1115376
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.7418880
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.0833876
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.6610280